Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
Peripheral neurotoxicity is a major complication associated with the use of chemotherapeutic agents such as platinum compounds, taxanes and vinca alkaloids. The neurotoxicity of chemotherapy depends not only on the anticancer agent(s) used, the cumulative dose and the delivery method, but also on the capacity of the nerve to cope with the nerve-damaging process. The sensory and motor symptoms and signs of neurotoxicity are disabling, and have a significant impact on the quality of life of cancer patients. Moreover, the risk of cumulative toxicity may limit the use of highly effective chemotherapeutic agents. Therefore, prophylaxis and treatment of peripheral neurotoxicity secondary to chemotherapy are major clinical issues. Acetyl-L-carnitine (ALC), the acetyl ester of L-carnitine, plays an essential role in intermediary metabolism. Some of the properties exhibited by ALC include neuroprotective and neurotrophic actions, antioxidant activity, positive actions on mitochondrial metabolism, and stabilisation of intracellular membranes. ALC has demonstrated efficacy and high tolerability in the treatment of neuropathies of various aetiologies, including chemotherapy-induced peripheral neuropathy (CIPN). In several experimental settings, the prophylactic administration of ALC prevented the occurrence of peripheral neurotoxicity commonly induced by chemotherapeutic agents. In animal models of CIPN, ALC administration promoted the recovery of nerve conduction velocity, restored the mechanical nociceptive threshold, and induced analgesia by up-regulating the expression of type-2 metabotropic glutamate receptors in dorsal root ganglia. These results, plus the favourable safety profile of ALC in neuropathies of other aetiologies, have led to the effects of ALC on CIPN being investigated in cancer patients. Preliminary results have confirmed the reasonably good tolerability profile and the efficacy of ALC on CIPN. The present studies support the use of ALC in cancer patients with persisting neurotoxicity induced by paclitaxel or cisplatin treatment.
De Grandis
Domenico
D
Divisione di Neurologia, Ospedale Civile di Rovigo, Rovigo, Italy. ddegrandis@iol.it
D000108:Acetylcarnitine / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control
D000970:Antineoplastic Agents; D018697:Nootropic Agents; D000108:Acetylcarnitine
Clin Oncol (R Coll Radiol). 2005 Jun;17(4):271-6
15997923
Lung Cancer. 2004 Mar;43(3):247-57
15165082
Eur J Cancer. 2005 Aug;41(12):1746-50
16039110
Mol Pain. 2006 Jun 09;2:20
16764720
Tumori. 2005 Mar-Apr;91(2):135-8
15948540
Mol Pharmacol. 2002 May;61(5):989-96
11961116
J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91
15547181
Clin J Oncol Nurs. 2003 May-Jun;7(3):299-303
12793336
Cancer. 1990 Sep 15;66(6):1117-23
2169332
J Neurooncol. 1997 Oct;35(1):47-53
9266440
Pain. 2004 May;109(1-2):132-42
15082135
J Clin Oncol. 1992 May;10(5):718-26
1569444
Acta Neuropathol. 1992;84(4):364-71
1441917
Int J Gynecol Cancer. 1995 May;5(3):161-169
11578472
Int J Gynecol Cancer. 2003 Jul-Aug;13(4):428-34
12911718
Clin Cancer Res. 2003 Nov 15;9(15):5756-67
14654561
Neurology. 1998 Sep;51(3):868-70
9748043
Cancer Chemother Pharmacol. 1989;25(1):62-4
2556219
Neurology. 2005 Jan 11;64(1):26-31
15642899
Minerva Anestesiol. 2006 Mar;72(3):151-69
16493391
Drugs. 2003;63(15):1549-63
12887262
Anticancer Res. 2005 Jul-Aug;25(4):2681-7
16080512
Neurology. 1989 Mar;39(3):368-73
2564647
J Natl Cancer Inst Monogr. 1993;(15):107-15
7912516
Neurosci Lett. 2006 Apr 24;397(3):219-23
16406309
Ann Oncol. 1998 Apr;9(4):443-7
9636837
Semin Oncol. 2006 Feb;33(1):15-49
16473643